Physician profile
Jon Persichino
NPI 1619905189
$8,143.12
in general payments reported to CMS, 2019-2025
26 companies · $978 in 2025
The $978 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,893 · 2020: $229 · 2021: $661 · 2022: $1,910 · 2023: $679 · 2024: $793 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,724.92 | 2019-2025 | |
| Viiv Healthcare Company | $1,384.49 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Shionogi INC | $697.89 | 2021-2025 | Fetroja |
| Abbvie INC. | $336.93 | 2021-2025 | |
| Melinta Therapeutics, LLC | $256.75 | 2019-2024 | Kimyrsa, Rezzayo, Vabomere |
| Allergan, INC. | $234.55 | 2019-2020 | |
| Insmed, INC. | $168.99 | 2020-2021 | |
| Janssen Products, LP | $164.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $149.01 | 2019-2024 | Zerbaxa |
| Paratek Pharmaceuticals, INC. | $133.69 | 2024-2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $124.97 | 2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $119.93 | 2022 | |
| Astellas Pharma US INC | $113.01 | 2019-2024 | Cresemba |
| Janssen Biotech, INC. | $98.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.75 | 2023-2024 | Ofev |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86.02 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $56.96 | 2021 | |
| Lilly USA, LLC | $50.79 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $43.91 | 2023-2024 | Wegovy |
| Emd Serono, INC. | $26.92 | 2021 | |
| Recordati_rare_diseases_inc. | $25.66 | 2024 | Isturisa, Signifor Lar |
| Theratechnologies INC. | $20.00 | 2022 | |
| Baxter Healthcare | $19.42 | 2023 | Hillrom - Life 2000 Ventilation System |
| Xeris Pharmaceuticals, INC. | $17.45 | 2024 | Gvoke Hypopen |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Persichino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.